Upstream Bio Inc (UPB) Stock Price, Quote & News

Company Profile

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

Industry: Biotechnology

Sector: Healthcare

Phone: 781 208 2466

Website: upstreambio.com

Address:

890 Winter Street, Suite 200, Waltham, United States

Trainguy1 May. 15 at 3:26 PM

$UPB Upstream Bio will present new data on two posters from their Phase 2 VIBRANT trial of verekitug at the American Thoracic Society (ATS) 2026 International Conference in Orlando, Florida, on Monday, May 18, 2026, from 11:30 AM to 1:15 PM ET. The posters will be presented during the "B32 – Rise of the Biologics: A New Hope for Breathing Easier" session.

0 · Reply

Xrx12 May. 12 at 5:43 PM

$UPB should see $7S and lower soon 🙏. Will buy a lot then

0 · Reply

SuperGreenToday May. 8 at 3:08 AM

$UPB Share Price: $8.99 Contract Selected: Nov 20, 2026 $10 Calls Buy Zone: $0.85 – $1.05 Target Zone: $1.45 – $1.77 Potential Upside: 61% ROI Time to Expiration: 196 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Xrx12 May. 7 at 4:09 PM

$UPB keeping an eye as this looks like it'll drop off a cliff and give a great buying opportunity. Bearish for now

0 · Reply

Xrx12 May. 5 at 5:21 PM

$UPB Will revisit in low $8S or less

0 · Reply

Xrx12 May. 5 at 4:40 PM

$UPB I've sold - this stock is dead in the water, unfortunately. Seems like they're pulling from their $150M ATM and have no catalysts soon. Best of luck everyone!

0 · Reply

OfficialStocktwitsUser Apr. 28 at 8:31 PM

$UPB RSI: 45.27, MACD: -0.2482 Vol: 0.42, MA20: 9.76, MA50: 8.97 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

BillionerOfKing Apr. 27 at 5:57 PM

$UPB Current Stock Price: $9.27 Contracts to trade: $10.0 UPB May 15 2026 Call Entry: $0.32 Exit: $0.60 ROI: 91% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Cheaslea76 Apr. 16 at 10:05 AM

$UPB earning 26th March

1 · Reply

bababooey143 Apr. 15 at 2:44 PM

$UPB I'm out no volume

0 · Reply

Upstream Bio price target lowered to $50 from $51 at Mizuho

2026-05-13T12:54:52.000Z - 2 days ago

Upstream Bio reports Q1 revenue $1.03M, consensus $347,170

May 13, 2026, 7:00 AM EDT - 2 days ago

Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

2026-04-17T11:07:21.000Z - 4 weeks ago

Upstream Bio to present new data from Phase 2 Vibrant trial of Verekitug

Apr 17, 2026, 7:00 AM EDT - 4 weeks ago

Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference

2026-03-27T10:45:28.000Z - 7 weeks ago

Upstream Bio downgraded to In Line from Outperform at Evercore ISI

Mar 26, 2026, 7:00 AM EDT - 7 weeks ago

Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 9, 2026, 1:40 PM EDT - 2 months ago

Upstream Bio Transcript: Leerink Global Healthcare Conference 2026

Mar 4, 2026, 9:50 AM EST - 2 months ago

Upstream Bio Transcript: TD Cowen 46th Annual Health Care Conference

2026-03-01T16:35:25.000Z - 2 months ago

Upstream Bio announces verekitug met the primary endpoint

Mar 1, 2026, 9:45 AM EST - 2 months ago

Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting

Feb 26, 2026, 7:00 AM EST - 2 months ago

Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026

Feb 25, 2026, 7:00 AM EST - 2 months ago

Upstream Bio to Participate in Upcoming March Investor Conferences

Feb 11, 2026, 8:00 AM EST - 3 months ago

Upstream Bio Transcript: Study result

2026-02-11T11:15:40.000Z - 3 months ago

Upstream Bio reports results from Phase 2 VALIANT clinical trial

Feb 11, 2026, 6:00 AM EST - 3 months ago

Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma

Feb 10, 2026, 6:00 PM EST - 3 months ago

Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma

2026-01-20T19:55:30.000Z - 4 months ago

Upstream Bio management to meet virtually with Piper Sandler

Jan 12, 2026, 5:15 PM EST - 4 months ago

Upstream Bio Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 7:00 AM EST - 4 months ago

Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference

2025-12-17T21:16:04.000Z - 5 months ago

Upstream Bio initiated with an Outperform at Mizuho

Dec 4, 2025, 10:25 AM EST - 5 months ago

Upstream Bio Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 4:30 PM EST - 5 months ago

Upstream Bio Transcript: Piper Sandler 37th Annual Healthcare Conference

2025-12-02T12:15:17.000Z - 5 months ago

Upstream Bio initiated with an Outperform at LifeSci Capital

Nov 25, 2025, 7:00 AM EST - 6 months ago

Upstream Bio to Participate in Upcoming December Investor Conferences

2025-11-18T09:55:15.000Z - 6 months ago

Upstream Bio initiated with an Outperform at Evercore ISI

Nov 12, 2025, 10:30 AM EST - 6 months ago

Upstream Bio Transcript: TD Cowen Immunology and Inflammation Summit

Nov 11, 2025, 9:20 AM EST - 6 months ago

Upstream Bio Transcript: Stifel 2025 Healthcare Conference

2025-11-05T12:40:50.000Z - 6 months ago

Upstream Bio files automatic mixed securities shelf

2025-11-05T12:22:15.000Z - 6 months ago

Upstream Bio reports Q3 revenue $683k, consensus $516.8k

Nov 5, 2025, 7:00 AM EST - 6 months ago

Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress

Oct 31, 2025, 7:00 AM EDT - 7 months ago

Upstream Bio to Participate in Upcoming November Investor Conferences

Sep 30, 2025, 4:15 AM EDT - 8 months ago

Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress

Sep 15, 2025, 10:30 AM EDT - 8 months ago

Upstream Bio Transcript: Stifel Virtual Immunology and Inflammation Forum

Sep 9, 2025, 7:00 AM EDT - 8 months ago

Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Sep 2, 2025, 8:00 AM EDT - 9 months ago

Upstream Bio Transcript: Study Update

Sep 2, 2025, 6:00 AM EDT - 9 months ago

Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Sep 1, 2025, 5:00 PM EDT - 9 months ago

Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Aug 6, 2025, 7:00 AM EDT - 10 months ago

Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress

Jul 8, 2025, 7:00 AM EDT - 11 months ago

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

Jun 15, 2025, 7:45 AM EDT - 11 months ago

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Jun 11, 2025, 9:20 AM EDT - 1 year ago

Upstream Bio Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 5, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025

Jun 4, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 20, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio Appoints Stacy Price as Chief Technology Officer

May 6, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs

Mar 12, 2025, 1:40 PM EDT - 1 year ago

Upstream Bio Transcript: Leerink Global Healthcare Conference 2025

Mar 12, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Mar 4, 2025, 11:50 AM EST - 1 year ago

Upstream Bio Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 25, 2025, 8:00 AM EST - 1 year ago

Upstream Bio to Present at Upcoming March Investor Conferences

Jan 13, 2025, 5:15 PM EST - 1 year ago

Upstream Bio Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Dec 16, 2024, 8:00 AM EST - 1 year ago

Upstream Bio Announces Addition to Russell 2000® Index

Dec 3, 2024, 2:00 PM EST - 1 year ago

Upstream Bio Transcript: Piper Sandler 36th Annual Healthcare Conference

Oct 15, 2024, 4:15 PM EDT - 1 year ago

Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Oct 11, 2024, 12:49 PM EDT - 1 year ago

Upstream Bio valued at $1.1 bln as shares jump in Nasdaq debut

Oct 10, 2024, 7:42 PM EDT - 1 year ago

Upstream Bio raises $255 mln in US IPO

Oct 10, 2024, 7:35 PM EDT - 1 year ago

Upstream Bio Announces Pricing of Upsized Initial Public Offering

Trainguy1 May. 15 at 3:26 PM

0 · Reply

Xrx12 May. 12 at 5:43 PM

$UPB should see $7S and lower soon 🙏. Will buy a lot then

0 · Reply

SuperGreenToday May. 8 at 3:08 AM

0 · Reply

Xrx12 May. 7 at 4:09 PM

$UPB keeping an eye as this looks like it'll drop off a cliff and give a great buying opportunity. Bearish for now

0 · Reply

Xrx12 May. 5 at 5:21 PM

$UPB Will revisit in low $8S or less

0 · Reply

Xrx12 May. 5 at 4:40 PM

$UPB I've sold - this stock is dead in the water, unfortunately. Seems like they're pulling from their $150M ATM and have no catalysts soon. Best of luck everyone!

0 · Reply

OfficialStocktwitsUser Apr. 28 at 8:31 PM

0 · Reply

BillionerOfKing Apr. 27 at 5:57 PM

0 · Reply

Cheaslea76 Apr. 16 at 10:05 AM

$UPB earning 26th March

1 · Reply

bababooey143 Apr. 15 at 2:44 PM

$UPB I'm out no volume

0 · Reply